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Background. Glioblastoma (GBM) is the most common primary brain tumor, with dismal prognosis. The failure of drug–radiation 
combinations with promising preclinical data to translate into effective clinical treatments may relate to the use of simplified 
2-dimensional in vitro GBM cultures.
Methods. We developed a customized 3D GBM culture system based on a polystyrene scaffold (Alvetex) that recapitulates key 
histological features of GBM and compared it with conventional 2D cultures with respect to their response to radiation and to 
molecular targeted agents for which clinical data are available.
Results. In 3 patient-derived GBM lines, no difference in radiation sensitivity was observed between 2D and 3D cultures, as 
measured by clonogenic survival. Three different molecular targeted agents, for which robust clinical data are available were 
evaluated in 2D and 3D conditions: (i) temozolomide, which improves overall survival and is standard of care for GBM, exhibited 
statistically significant effects on clonogenic survival in both patient-derived cell lines when evaluated in the 3D model compared 
with only one cell line in 2D cells; (ii) bevacizumab, which has been shown to increase progression-free survival when added to 
standard chemoradiation in phase III clinical trials, exhibited marked radiosensitizing activity in our 3D model but had no effect 
on 2D cells; and (iii) erlotinib, which had no efficacy in clinical trials, displayed no activity in our 3D GBM model, but radiosensi-
tized 2D cells.
Conclusions. Our 3D model reliably predicted clinical efficacy, strongly supporting its clinical relevance and potential value in 
preclinical evaluation of drug–radiation combinations for GBM.
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Glioblastoma (GBM) is the most common primary brain tumor 
and is associated with dismal prognosis.1 Tumors exhibit inher-
ent chemo- and radioresistance, which has been attributed to 
a subpopulation of cancer cells termed ‘GBM stem-like cells’ 
(GSC).2 Comprehensive genomic and molecular characteriza-
tion of GBM has identified a number of promising targets, and 
preclinical studies have shown activity of several molecularly 
targeted agents against GBM cell lines.3 To date, however, 
these agents have failed to improve clinical outcomes for GBM 
patients.4 One explanation for the discrepancy between pre-
clinical and clinical data may be the lack of preclinical models 
that faithfully recapitulate the clinical scenario. In particu-
lar, established cancer cell lines cultured in simplified 2D in 
vitro systems undergo profound phenotypical changes and 
have been reported to exhibit markedly different responses 
to cytotoxic treatments than those observed in patients.5 In 
the context of radiation therapy 3D culture of lung and head 
and neck cancer cells embedded in laminin-rich extracellular 
matrix (ECM) has been shown to promote radiation resistance 
compared with 2D culture.6–8 Colorectal cancer cell lines cul-
tured in similar laminin-rich ECM 3D conditions also exhibited 
changes in cellular morphology, phenotype, and gene expres-
sion and were resistant to treatment with epidermal growth 
factor receptor (EGFR) inhibitors compared with 2D cells.5,9 
These observations provide a potential explanation for the fre-
quent failure of results derived from conventional 2D cell cul-
ture systems to predict clinical efficacy.10
To examine the hypothesis in the context of GBM, in which 
all molecular targeted agents so far tested in patients have 
been ineffective, we developed a customized 3D cell culture 
system that recapitulates key histological features of GBM such 
as high cellularity, a relative paucity of stromal components, 
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and the presence of radioresistant GSC. Patient-derived GBM 
cells were cultured in stem cell promoting medium in order to 
preserve the GSC phenotype. Based on accumulating evidence 
that GSC localize preferentially to hypoxic and perivascular 
regions associated with high levels of vascular endothelial 
growth factor (VEGF),11,12 and because GBM generally exhibit 
high levels of hypoxia and VEGF,13,14 the culture medium was 
supplemented with VEGF. Using this 3D model, we evaluated 
cellular responses to radiotherapy alone and in combination 
with molecular targeted agents previously assessed in the 
clinic and compared survival data with results derived from 2D 
simplified cultures and with data from clinical trials in GBM. Our 
data indicate that this novel 3D in vitro model may have broad 
utility as a clinically representative system in which to evaluate 
potential new therapies for this cancer of unmet need.
Materials and Methods
Cell Culture and Radiation Treatment
E2, R10, and G7 GBM cell lines were obtained from Colin Watts 
(Cambridge) and are derived from anonymized patient resec-
tion specimens as previously described.15,16 Cell lines were rou-
tinely cultured on Matrigel-coated plates (0.2347 mg/mL in Adv/
Dulbecco’s modified Eagle’s medium) in serum-free “stem cell” 
medium (Supplementary materials). For laminin-rich 3D cultures, 
cells were seeded in suspension in 1:2 diluted Matrigel (4.75 mg/
mL in stem cell media). For Alvetex 3D cultures, Alvetex scaffolds 
were permeabilized according to manufacturer’s instructions 
and coated with diluted Matrigel as for 2D cultures.
Clonogenic Survival Assays
Seeded were 250 cells per well in Matrigel-coated plates or 
scaffolds or embedded in Matrigel plugs for 3D-E experiments. 
Eighteen hours after seeding, cells were either sham irradiated 
or irradiated (1–9 Gy) and incubated for 2 to 3 weeks prior to 
methanol fixation and crystal violet staining. Visible colonies 
were counted manually. For 3D cultures, cells were incubated 
with MTT reagent and colonies counted manually. Curves rep-
resent mean surviving fraction ± SD of 3 independent experi-
ments (in triplicate) fitted to a linear quadratic model.
Mouse Experiments
Female CD1 nude mice were orthotopically injected with 
1 × 105 cells grown for 7 days in 3D-Alvetex scaffolds or in 2D 
conditions as previously performed.16 Mice were monitored 
for the duration of experiment and were sacrificed when they 
became symptomatic (isolated, hunched, reduced mobility, 
and/or weight loss greater than 20%).
Ethical Approval
Animal experiments were in compliance with all regulatory 
guidelines, as described in the Animals Act 1986 Scientific 
Procedures on living animals regulated by the Home Office in 
the United Kingdom.
Flow Cytometry
For 2D cultures, cells were detached from plastic by incuba-
tion with trypsin (1 mL) (Gibco) and fixed with 70% ice-cold 
ethanol/phosphate buffered saline (PBS). For 3D cultures, cells 
were detached with trypsin (1 mL per scaffold) and incubated 
for 15 min in a rotating platform at 30 rpm. Fixed cells were 
stained with 1 µg/mL propidium iodide/PBS in the presence of 
RNase A  (10 µg/mL). Cell cycle distribution was determined 
according to manufacturer’s instructions (BD Biosciences). 
Data were analyzed using FlowJo software (Tristar).
Protein Extraction
For 2D and 3D cultures, cells were incubated in 1% sodium 
dodecyl sulfate–Tris buffer for 20 min on ice; 3D cultures were 
transferred to a rotating platform at 100 rpm and incubated for 
10 min. Recovered lysates were clarified using Qiagen columns.
Gene Expression Array
Four days after plating cells in either 2D or 3D conditions, RNA 
was extracted with TRIzol reagent. RNA sequencing (RNA-seq) 
analysis was performed using the IlluminaNextSeq500 for a 
PolyA selection RNA library, with a paired-end sequencing 
model and 33M depth for triplicate experimental repeats of 
2D and 3D G7 or E2 cultures. Differential transcript expression 
analysis was performed using TopHat and Cufflinks. Expression 
array data were analyzed according to the following criteria: 
statistical significance was set at q value of <0.1, where P value 
was set at <.05.
Quantitative Real-Time PCR
Cells were grown as for gene expression array assays, 
RNA extraction was performed using TRIzol reagent (Life 
Technologies), and cDNA was prepared using the Quantitech 
Reverse Transcription Kit (Qiagen, cat. no. 205311), both as per 
manufacturer’s instructions. Quantitative PCR was conducted 
using SYBR green (Quanta, cat. no.  95072-012) and the Bio-
Rad CFX platform, with a 60ºC annealing temperature and the 
primer pairs that are tabulated in the Supplementary materials.
Fluorescence In situ Hybridization Assay
Cells were grown in either 2D or 3D conditions for 4 days and 
fixed with 2% paraformaldehyde for 15 min. Fluorescence in 
situ hybridization (FISH) analysis was performed using a histol-
ogy FISH Accessory Kit (Dako, cat. no. K5799) and an EGFR/
CEN-7 FISH probe mix (Dako, cat. no. Y5500) according to 
manufacturer’s instructions. Z-stack images were acquired 
using a Zeiss 780 confocal microscope with a 63× magnifica-
tion objective and analyzed with Zen black software.
Immunofluorescence
Cells were plated at identical seeding densities either on 
Matrigel-coated coverslips or on Matrigel-coated Alvetex 
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scaffolds. Fixed cells (2% paraformaldehyde/PBS) were per-
meabilized with 1% Triton/PBS, blocked with 2% bovine serum 
albumin/Tris-buffered saline/0.5% Tween-20, and incubated 
with phalloidin for actin detection (Abcam) or with the respec-
tive primary antibodies (Supplementary materials). Nuclei 
were counterstained with 4′,6′-diamidino-2-phenylindole 
(DAPI) present in mounting medium (VectaShield).
Statistical Analyses
All experiments were performed in triplicate and data points 
reported as ±SEM. P values were obtained using the unpaired 
2-tailed t-test in GraphPad Prism software. Kaplan–Meier 
mouse survival curves were analyzed using Minitab 17 
Statistical software with pairwise comparisons and log rank 
(Mantel–Cox) analysis.
Results
Characterization of Primary GSC Cultured in the Novel 
3D-Alvetex System
Previously published 3D cancer models have generally repro-
duced the characteristics of carcinomas, in which cells are 
embedded in a dense, laminin-rich microenvironment and 
are thus inappropriate for GBM studies. In GBM, laminin 
expression is sparse and generally restricted to blood vessels 
(Supplementary Fig. 1A 17). Using Alvetex technology,18 we 
established a novel in vitro GBM model which promotes 3D 
growth of patient-derived GSC on a polystyrene scaffold. To 
replicate the perivascular stem cell niche, cells were cultured 
in serum-free stem cell medium supplemented with VEGF as 
well as EGF and basic fibroblast growth factor, which are rou-
tinely used in GSC cultures,19 and both 2D and 3D surfaces were 
coated with diluted (1:40) laminin-rich ECM (Supplementary Fig. 
1B). Three-dimensional cultures recapitulated the histopatho-
lolgical features of GBM in general and of orthotopic xenografts 
derived from the corresponding cell cultures in particular. Key 
features include high cellularity (G7 cell line: Fig. 1A, left pan-
els), invasion (E2 cell line: Fig. 1A, right panels), and hypoxic 
regions (Fig. 1B). The specific hypoxia marker pimonidazole 
revealed cell line dependent effects of the 3D model on oxygen 
concentrations: pimonidazole staining was barely detectable in 
3D G7 cultures but was observed in approximately 20% of sec-
tions obtained from 3D E2 cultures (Fig. 1B). These observations 
were supported by direct measurements made with an oxy-
gen probe (OxyLite, Oxford Optronics) applied to the surface of 
scaffolds: oxygen levels in G7 3D cultures were generally higher 
and more uniform (mean value 68.9 ± 4.03 mmHg, 9.06% 
O2) than those in E2 cultures, which ranged from 20.6 ± 2.07 
mmHg (2.6% O2) to 63.6 ± 6.48 mmHg (8.48 O2) depending on 
the region measured. GSC cultured in 3D conditions acquired a 
spherical morphology that contrasted with the flattened, elon-
gated morphology typical of adherent cells in 2D culture (Fig. 
1C). By promoting highly cellular and invasive 3D growth of GSC 
in reduced ECM conditions, the model recapitulates essential 
features of the GBM microenvironment
Cells in 3D cultures displayed reduced proliferation rates 
compared with 2D (Fig.  1D, day 7), consistent with the 
non-exponential growth profiles observed in vivo and with 
other published 3D models in vitro.20 VEGF supplementation 
increased 3D cell proliferation and had no effect on 2D con-
ditions (Supplementary Fig. 2A). Three-dimensional culture 
had no effect on cell cycle distribution in G7 cells; however, 
reduced G2/M populations and increased sub-G1 populations 
were observed in 3D cultured E2 cells (Fig. 1E), which can be lik-
ened to the high prevalence of cell loss and necrosis observed 
in GBM, and these effects were not affected by VEGF addition 
(Supplementary Fig. 2B and 2C, respectively).
Primary 3D Culture Preserves the GBM Stem-like 
Phenotype
G7 and E2 cells cultured in both 2D and 3D conditions retained 
expression of the putative stem cell markers nestin, Sox2, and 
cleaved Notch1 as assessed by immunofluorescence (Fig. 2A) 
and western blot (Fig. 2B). Removal of VEGF from 3D culture 
medium was associated with increased expression of the dif-
ferentiation marker glial fibrillary acidic protein and a decrease 
in stem cell marker expression but had no effect on these 
parameters in 2D cultures (Supplementary Fig. 3). Indeed, the 
negative effects of VEGF deprivation on 3D culture “stemness” 
were equivalent to the well-established differentiating effects 
of fetal calf serum on 2D cultures (Supplementary Fig. 3). 
These data corroborate VEGF’s role in maintaining a cancer 
stem cell phenotype in 3D conditions,21,22 and the absence of 
effect in 2D models emphasizes the critical influence of the 
3D microenvironment on growth factor signaling. Consistent 
with the stem cell marker data, neurosphere formation capac-
ity, a well-established surrogate of the GSC phenotype, was 
preserved and equivalent in cells cultured in 2D or 3D condi-
tions (Fig. 2C); and in vivo tumorigenicity, the gold standard 
assay of the cancer stem cell phenotype, was also maintained. 
Tumors were generated in 100% of immunocompromised 
mice (Crl:NU(NCr)-Foxn1nu) subjected to intracranial injection 
of G7 GSC that had been cultured in either 2D or 3D conditions, 
and no statistical significant difference in mouse survival was 
observed (Fig. 2D). In the case of E2 cells, 8/8 mice injected 
with 2D cultured GSC generated tumors detectable on histol-
ogy compared with 7/8 mice injected with 3D GSC. However, 
whereas most mice from the 3D GSC cohort had become 
symptomatic by the end of the study (140 days after injec-
tion), only 2 mice from the 2D cohort developed symptoms 
(Fig. 2D). Accelerated tumor progression was also observed in 
mice injected with CD133+ E2 cells sorted by flow cytometry 
(data not shown), indicating that the 3D microenvironment 
recapitulates the tumorigenic attributes of the stem cell niche. 
Similarly, G7 tumors derived from 2D and 3D GSC displayed 
key histopathological features of GBM, including high rates of 
cellular proliferation and mitosis, and infiltrative growth along 
white matter tracts (Fig. 2E and 2F). Tumors derived from 3D 
and 2D cultured E2 cells expressed high levels of the prolifera-
tion marker Ki67 and were remarkably invasive: in these mice, 
human leukocyte antigen‒1ABC (HLA) positive tumor cells 
were detected in both hemispheres and frequently localized 
around blood vessels (Fig. 2E and 2F). Together these results 
demonstrate that GSC cultured in the novel 3D system retain 
 at Periodicals D
ept on Septem
ber 13, 2016
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
Gomez-Roman et al.: Drug and radiation responses of a 3D glioblastoma model
4
Fig. 1. Characterization of GSC grown in 3D conditions. (A) Representative hematoxylin and eosin and human leukocyte antigen images of ortho-
topic tumors derived from intracranially injected G7 or E2 cells, respectively, and G7 or E2 cells grown on 3D-Alvetex scaffolds. (B) GSCs were 
grown in Alvetex scaffolds and incubated with pimonidazole one hour prior to fixation (2% paraformaldehyde). Scaffolds were immunostained 
using an anti-pimonidazole antibody (green) and counterstained with DAPI (blue). Two representative images of 3D cultures are shown for each 
cell line. (C) Immunofluorescent images of F-actin (Alexa Fluor 568 Phalloidin, red) and nuclear staining (DAPI; blue) of cells in 3D and 2D GSC con-
ditions. (D) G7 and E2 GSC (5x104) were seeded in 12-well Alvetex scaffolds or in T25 flasks and proliferation of 2D and 3D cultured cells measured 
according to Alvetex scaffolds MTT viability assay instructions (http://reinnervate.com/using-alvetex/workflow-2-culturing-monitoring-3d-cell-
growth/). Graph of mean±SD (n = 3). Statistical significance is observed in both cell lines at day 7 (t-test, P<.005). (E) Cell cycle distribution of GSC 
cultured in 2D or 3D conditions for 24 hours and analyzed by flow cytometry after propidium iodide staining (n = 3). Graph of mean±SEM (n = 3).
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Fig. 2. GSCs grown on 3D conditions retain their stemness and tumorigenicity. (A, B) Immunofluorescent images (A, scale bar 50 µm) and west-
ern blot analysis (B) of E2 and G7 GSCs grown on 2D or 3D conditions of stem cell marker expression. (C) Neurosphere formation assays for G7 and 
E2 GSC previously grown for 7 days in 2D or 3D stem cell conditions. Mean values ±SEM (n = 3). (D) Kaplan–Meier survival curves showing overall 
survival of individual cohorts of mice orthotopically injected with G7 and E2 cells grown on 2D or 3D conditions. Pairwise comparisons using log 
rank (Mantel–Cox) analysis: E2 2D versus E2 3D cells P = .082; G7 2D versus 3D cells P = .519. (E and F) Hematoxylin and eosin, Ki67, and human 
leukocyte antigen (HLA) immunohistochemistry of paraffin-embedded brain sections containing orthotopic tumors derived from intracranially 
injected G7 cells or E2 cells grown in 2D conditions (E) or 3D conditions (F) for 7 days prior to injection (n = 8). → indicates mitotic bodies.
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their tumorigenic potential and generate orthotopic tumors 
that recapitulate the GBM phenotype.
Radiation Responses of GSC in 2D and 3D Cultures
To evaluate the impact of 2D and 3D culture conditions on radi-
ation responses of GSC, clonogenic survival assays were con-
ducted in the relevant models, with cell irradiation and colony 
formation taking place in situ, and similar plating efficiencies 
were observed in the 2D and 3D models (data not shown). To 
distinguish between 3D growth and ECM effects, clonogenic sur-
vival experiments were initially conducted using GSC cultured 
either as monolayers on ECM-coated plates (2D) or embedded 
in laminin-rich ECM (3D-E), which has previously been shown 
to increase radiation resistance in lung and head and neck 
carcinoma cell lines.6 GSC cultured in 3D-E conditions were sig-
nificantly more radioresistant than corresponding 2D cultures, 
consistent with previous studies in other cell types (Fig. 3A, B). 
In contrast, the radiation sensitivity of E2 and G7 cells cultured 
in the 3D-Alvetex scaffold (3D) model was equivalent to that 
observed in 2D cultures, except for the R10 primary cell line, in 
which a modest increase in radiosensitivity was observed in 3D 
(Fig. 3C, 3D). This novel finding indicates firstly that ECM con-
centrations can affect ligand binding and effects of ligands on 
signaling and cell behavior, which might have a greater influ-
ence on radiation resistance than 3D growth per se and sec-
ondly that 3D in vitro models must be tailored to reflect the 
microenvironmental features of the relevant tumor type.
Changes in cellular morphology and an associated 
increase in heterochromatin have previously been reported 
to account for the radioprotection observed in 3D-E condi-
tions.6 In our 3D-Alvetex cultures, GSC acquired a spherical 
morphology that was distinct from the flattened, elongated 
morphology of the 2D populations (Fig. 1C). In contrast, cells 
grown in 3D-E conditions, while less flattened than 2D cells, 
acquired a more elongated morphology than cells cultured 
on the scaffold. Furthermore, western blot analysis revealed 
no effect of 3D-Alvetex culture on levels of heterochromatin 
protein 1; indeed, a slight increase in histone H3 acetylation 
(a marker of euchromatin) was observed (Fig. 3E). These 
observations are consistent with RNA-seq data (see below), 
which showed decreased expression of histone deacetylase 
genes in 3D GSC populations (Table 1). Taken together, our 
results indicate no association among chromatin condensa-
tion, cellular morphology, and radiation sensitivity in GSC.
Because the high cellularity and low stromal component of 
the 3D-Alvetex model more closely resembled the GBM micro-
environment, we subsequently focused on characterizing radi-
ation responses of GSC in this model, with the primary aim of 
validating it as a clinically relevant model of GBM.
Regions of low oxygen concentration (hypoxia) are a car-
dinal feature of GBM, and it is widely recognized that hypoxic 
cells are radioresistant.23 To document the impact of hypoxia 
on radiation responses of 3D GSC and to more closely mimic 
the hypoxic cancer stem cell niche, clonogenic survival assays 
were performed under oxic (21% O2) and clinically relevant 
hypoxic conditions (0.5% O2). As expected, cells were signifi-
cantly more radioresistant at 0.5% O2 than at 21% O2 (Fig. 3F). 
These results demonstrate that hypoxia confers further radio-
protection to the already radioresistant 3D GSC populations, 
and add further weight to our hypothesis that the 3D model 
can recapitulate key features of GBM.
The EGFR Tyrosine Kinase Inhibitor Erlotinib Enhances 
Radiosensitivity of 2D GSC but Has No Effect in 3D 
Cultures
In the past decade, a series of international, multicenter, phase 
III randomized studies have failed to improve outcomes for 
patients with GBM, either through intensification of chemother-
apy or addition of molecular targeted therapies such as cilen-
gitide or EGFR inhibitors such as erlotinib to standard treatment. 
Results of phase II trials studying the addition of molecular tar-
geted agents including erlotinib to standard therapy have been 
equally discouraging.24–26 EGFR gene amplification is a common 
feature of GBM that is associated with poor prognosis,27 and a 
number of preclinical studies have demonstrated radiopotenti-
ating efficacy of erlotinib in conventional 2D GBM cultures.28 A 
modest amplification of the EGFR gene in our patient-derived 
cell lines was observed, with no difference between 2D and 3D 
populations (Fig. 4A). G7 and E2 cells also exhibited chromo-
some 7 gain (centromere to chromosome 7 staining by FISH, 
red, Fig. 4A), a typical cytogenetic feature of GBM. Motivated by 
the large disparity between the preclinical and clinical effects 
of erlotinib, we selected this drug to investigate whether the 
3D model provides a more clinically relevant system than 2D 
cell culture. EGFR expression and activation in E2 and G7 GSC 
grown in 2D and 3D conditions expressed similar levels of total 
and activated (phospho-Y1092) EGFR protein both in orthotopic 
xenografts derived from cells cultured in 2D and 3D conditions 
and in vitro (Fig. 4B, Supplementary Fig. 4A). Erlotinib inhibited 
EGFR activity in both 2D and 3D G7 cultures as demonstrated by 
decreased phosphorylation of its active sites (Y1173 and Y1092) 
at baseline and following radiation treatment (Fig. 4C); however, 
no single agent activity of erlotinib was observed in either 2D or 
3D GSC in 3 different primary GBM cell lines, as assessed by clo-
nogenic formation efficiency (Fig. 4D). In contrast, the effects of 
erlotinib on radiation sensitivity were profoundly affected by the 
microenvironment. While erlotinib significantly enhanced the 
radiosensitivity of 2D cultures of all 3 cell lines, it had no effect 
on radiation sensitivity in the 3D model (Fig. 4E). No radiosen-
sitization by erlotinib was confirmed in neurosphere formation 
assays (Supplementary Fig. 4C), a clinically relevant measure of 
GSC survival and self-renewal in which single cells generate 3D 
sphere structures devoid of a scaffold or extrinsic ECM, although 
a reduction in neurosphere formation efficiency was observed 
following erlotinib treatment alone (Supplementary Fig. 4B). 
Hence while EGFR activation might be required for GBM tum-
origenicity, our data demonstrate that EGFR inhibition has no 
therapeutic effect in 3D models in combination with radiation.
The Novel 3D GSC Model Recapitulates the Activity of 
Temozolomide and Bevacizumab Observed in the Clinic
Next, we evaluated 2 agents that have documented clinical activity 
against GBM: temozolomide, which is part of standard of care1,29; 
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Fig. 3. Radiation responses of GSC in 2D and 3D conditions. (A, C) Representative images of GSC colonies after 21 days growing on plastic (2D), 
embedded in Matrigel (3D-E, A) or in 3D-Alvetex scaffolds (3D, C). (B, D) Clonogenic survival curves of G7 and E2 cells grown in 2D and 3D-E (B) 
or 2D and 3D-Alvetex scaffold conditions (D) and irradiated with single doses of X-rays (0–9 Gy; n = 3). Curves are significantly different in (B) for 
both cell lines by 2-way ANOVA (2D vs 3D-E P < .0001, calculated by ANOVA general linear model. No statistical significance was observed for 2D 
versus 3D G7 (P = .1) or E2 (P = .1) data in (D). R10 3D cultures were significantly more radiosensitive than 2D cultures (P = .01). (E) Western blot 
analysis of G7 and E2 cell lysates extracted from cells grown in 2D or 3D. (F) Clonogenic survival curves as (D). Hypoxic cultures of both G7 and E2 
GSCs are significantly more resistant than normoxic cultures (2-way ANOVA analysis; P = .0021 and P = .0004, respectively).
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and the anti-VEGF monoclonal antibody bevacizumab, which is 
the only molecular targeted agent to have shown evidence of 
radiopotentiating activity against GBM in the form of increased 
progression-free survival in 2 randomized phase III trials.30,31 
Constitutive activation of the VEGF receptor VEGFR2 was observed 
in G7 and E2 orthotopic xenografts (Fig. 5A). Bevacizumab treat-
ment alone had no effect on clonogenic efficiency of GSC in 2D 
or 3D conditions (Fig.  5B). In contrast, whereas bevacizumab 
treatment significantly radiosensitized 3D GSCs, but had no radio-
sensitizing activity in 2D cultures (Fig. 5C and 5 D, respectively). 
Bevacizumab also significantly potentiated the effects of radia-
tion on neurosphere formation of both cell lines (Supplementary 
Fig. 4E), as well as presenting activity as a single agent in the E2 
cell line (Supplementary Fig. 4D). Radiosensitization in this alter-
native 3D model confirmed our findings in the 3D-Alvetex system 
and reproduced the effects observed in clinical trials.
Consistent with this 3D-specific effect, VEGFR2 protein levels 
were higher in 3D cells than 2D cells in the absence of VEGF, and 
the active, phosphorylated form of VEGFR2 was only detected 
in 3D G7 cells (Fig. 5E). Although addition of VEGF induced 
expression of VEGFR2 in 2D GSC and differentiated cells, no 
detectable levels of phosphorylated VEGFR2 were observed.
Finally, activity of the clinically active agent temozolomide 
on 2D and 3D GSC cultures was assessed. Treatment with 
temozolomide significantly reduced the clonogenic efficiency 
of 3D GSC in both G7 and E2 GSCs, whereas in 2D conditions 
this cytotoxic effect only reached statistical significance in the 
E2 cell line (Fig. 5F). Taken together, these findings corroborate 
our hypothesis that the novel 3D GBM culture system repli-
cates effects observed in the clinic, both negative and positive 
clinical outcomes, and will facilitate meaningful preclinical 
assessment of novel molecular targets.
Genome-wide Gene Expression Analysis in 2D and 
3D GSC
Expression array analysis was performed to identify specific 
gene expression patterns associated with 2D and 3D culture 
conditions which might explain differential responses to treat-
ment. Comparison of 2D and 3D datasets demonstrated a 
higher number of genes to be differentially expressed in G7 
(4027 genes) than E2 (361 genes) GSCs (full list provided in 
Table S1). Found to be upregulated were 2108 transcripts and 
1916 downregulated in G7 GSC grown on 3D conditions com-
pared with 2D, while 222 transcripts were upregulated and 
137 downregulated in E2 3D cells. When the 2 cell lines were 
matched together, 160 transcripts were differentially expressed 
in 2D versus 3D in both cell lines (80 upregulated, 35 downregu-
lated, and 45 exhibiting opposite expression patterns).
Gene ontology analysis of upregulated transcripts in 3D 
conditions by protein class using Panther32 identified genes 
associated with receptor, transporter, and transcription fac-
tor activity (Fig. 6A). These include genes associated with the 
EGFR pathway such as EREG,33 ABCA1 and ABCA2,34 IGFBP4,35 
PTPN13,36 and NOTCH337; and with VEGFR activity such as 
VEGFA and EDNRB. Cellular component analysis revealed an 
increase in expression of genes belonging to the organelle, 
membrane (100% belonging to cytoskeleton), extracellu-
lar region, and ECM categories (Fig. 6A). Of note, increased 
expression of genes associated with “stemness” (eg, CEBPD, 
NOTCH3, ID; and Wnt signaling) was observed in 3D cultures 
(Supplementary Fig. 6B). Several genes from the “mesenchy-
mal” GBM signature were upregulated in 3D cultures of both 
E2 and G7 cells, including CHI3L1, RELB, FN1, VIM, and CEBPD 
(Supplementary Fig. 6A); however, our transcriptome data 
revealed no clear segregation of our cultures with the pro-
posed GBM subtypes previously reported,38 exemplifying the 
intratumoral transcriptional heterogeneity observed in GBM.39
Quantitative real-time PCR validation of the transcriptome 
data regarding the 3D versus 2D comparison of 20 genes con-
firmed upregulation of the selected target genes with 100% suc-
cess rate (Fig. 6C). Immunofluorescence analysis of G7 3D cells 
confirmed upregulation of the cytoskeleton proteins vimentin 
and glial fibrillary acidic protein in 3D compared with 2D G7 cells, 
recapitulating human GBM immunohistochemistry (Fig. 6D).
Although different patterns were observed in the 2 cell lines 
studied, the marked changes in cytoskeleton, transcriptional 
activity, and receptor activity associated with the transition 
to 3D culture are consistent with the observed morphological 
changes and might explain the different effects of molecular 
targeted therapies against EGFR or VEGFR observed in the 2D 
and 3D models.
Discussion
Here we describe a customized, 3D cell culture system that 
recapitulates key histological features of GBM. Our data indi-
cate that (i) responses of GBM cells to growth factor recep-
tor therapies in combination with radiation are profoundly 
affected by 2D versus 3D culture; (ii) meaningful preclinical 
assessment of these and other molecular targeted agents 
requires experimental models that recapitulate key features of 
tumors in vivo; and (iii) the 3D GBM model developed in our 
laboratory has potential value in these analyses. The new 3D 
model reproduced the clinical results of 3 molecular targeted 
therapies, demonstrating its reliability predicting clinical out-
comes and indicating superiority over conventional 2D models 
which have failed to predict clinical efficacy.
In the context of radiation therapy, 2D and 3D GSC exhib-
ited similar sensitivity in our models, which might be explained 
Table 1. Reduced expression of histone deacetylases in 3D GSC com-
pared with 2D GSC
Gene Locus Log2_fold 
2D v 3D
Cell  
Line
Significance
(P value)
HDAC5 chr17:42154120-42201014 −0.28206 G7 .02705
HDAC6 chrX:48660486-48683380 −0.24577 G7 .0224
HDAC7 chr12:48166966-48213763 −0.61262 G7 5.00E-05
−0.53918 E2 .03
HDAC9 chr7:18126571-19036992 −0.84383 G7 .00065
−0.8634 E2 5.00E-05
Source: RNA sequencing (RNA-Seq) analysis of gene expression 
performed on G7 and E2 cells grown on plastic (2D) or 3D- Alvetex 
scaffolds (3D).
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Fig. 4. Radiosensitization of GSCs by EGFR inhibition is determined by growth conditions. (A) Representative immunofluorescence images of EGFR 
gene (green) and chromosome 7 centromere (red) staining by FISH assay in G7 and E2 2D and 3D GSC. Nonnuclear staining reflects background 
autofluorescence. (B) Representative immunohistochemistry images of phosphorylated and total EGFR in G7 and E2 orthotopic tumors from 
cells grown on 3D or 2D conditions for 7 days. (C) Protein extracts of G7 GSCs grown in 2D or 3D conditions obtained at different time points after 
treatment with erlotinib (1 µM) and/or ionizing radiation (5 Gy) were analyzed for total and phosphorylated EGFR by western blot. Actin served 
as loading control. (D) Clonogenic survival efficiency of G7, E2, and R10 cells treated with either vehicle (dimethyl sulfoxide [DMSO]) or erlotinib 
(1 µM) 20 hours following seeding and left for the duration of the experiment (18 days). Graph depicts mean±SD. (E) Clonogenic survival of G7, E2, 
and R10 cells grown in 2D and 3D conditions and irradiated with single doses of X-rays (0–6 Gy; n = 3) 2 hours after treatment with erlotinib (1 µM) 
or DMSO. Erlotinib treatment significantly increased the radiosensitivity of G7, E2, and R10 GSCs under 2D conditions (ANOVA; P < .0001, P = .0006, 
and P = .0016, respectively). No effect of erlotinib was observed in 3D conditions compared with DMSO (G7 P = .1; E2 P = .1007 and R10 P = .842).
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Fig. 5. Radiosensitization of GSCs by bevacizumab and temozolomide is determined by growth conditions. (A) Representative immunohisto-
chemistry images of phospho-VEGFR2 in G7 and E2 orthotopic tumors grown from 3D GSC. (B) Clonogenic survival efficiency of G7 and E2 cells 
treated with either vehicle (PBS) or bevacizumab (0.1 µg/mL) 20 hours following seeding and left for the duration of the experiment (18 days). 
Graph depicts mean±SD. (C and D) Clonogenic survival of G7, E2, and R10 cells grown in 3D (C) and 2D (D) conditions and irradiated with single 
doses of X-rays (0–6 Gy; n = 3) 2 hours after treatment with bevacizumab (0.1 µg/ mL) or vehicle (PBS). Bevacizumab treatment significantly 
increased the radiosensitivity of G7 and E2 GSCs under 3D conditions (ANOVA; control vs bevacizumab P < .01 and P < .05, respectively). (E) Protein 
extracts of G7 GSCs grown in 2D or 3D conditions in the absence or presence of VEGF-A (30 ng/mL) were analyzed for total and phospho-VEGFR2 
by western blot. (F) Clonogenic survival efficiency of G7 and E2 cells treated with either vehicle (dimethyl sulfoxide; DMSO) or temozolomide 
(10 µM) as in (B). Statistical significance (t-test) *P < .05, **P < 0.05.
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Fig. 6. RNA-seq analysis of 3D versus 2D GSC cultures. (A) Gene ontology (GO) analysis of transcripts significantly upregulated in the 3D model 
in both G7 and E2 cultures. GO of molecular function (upper chart) and cellular components (lower chart) are represented. (B) Bar charts repre-
senting differentially expressed genes in 3D compared with 2D G7 and E2 cells within the cytoskeleton, extracellular matrix region, and receptor 
activity categories. (C) Real-time PCR validation of representative genes upregulated in the 3D GBM model. Bars represent mean±SD of cDNA 
expression from 3 independent experiments performed in duplicate. t-Test *P < .05; **P < .005. (D) Immunofluorescent images of vimentin (upper 
panel) and glial fibrillary acidic protein (lower panel) of G7 cells grown in either 2D or 3D conditions.
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by the stem cell culture conditions that enrich for the radiore-
sistant GSC population. Further characterization of our 3D GBM 
model in terms of proteomics, metabolomics, and biophysical 
properties such as stiffness will further our understanding of 
the potential value of our model in evaluating radiation, drug, 
and radiation–drug responses.
One important feature of our 3D model was the require-
ment for VEGF supplementation for stem cell phenotype pres-
ervation, as previously identified for EGF and basic fibroblast 
growth factor.24 VEGF promotes neurosphere formation in 
GSC cultures21 and proliferation of neural stem cells,40 which 
share common features with GSCs. Our 3D model not only 
corroborates VEGF’s role in promoting GSC proliferation (see 
Supplementary Fig. 4B), but also implicates VEGF in cell fate 
determination. This “stemness” function of VEGF is not novel 
but importantly has only been observed in vitro in 3D cancer 
stem cell conditions such as neurospheres,21 or when studied 
in vivo.22 This mechanistic observation is of biological inter-
est and corroborates the clinical significance of our 3D model. 
Understanding how VEGF enhances the cancer stem cell phe-
notype will be critical for developing effective therapeutic strat-
egies to target GSC populations. Our data indicate that there 
may yet be potential in targeting the VEGF signaling pathway in 
GBM but that greater understanding of this complex pathway 
is required in order to identify the best therapeutic approach. 
Because both endothelial and tumor cells secrete VEGF, block-
ing paracrine and autocrine VEGF/VEGFR2 autocrine loops may 
be required to achieve remission and long-term cure.
Overall, the results obtained from our 3D GSC model repli-
cate the therapeutic responses to molecular targeted thera-
pies observed in GBM clinical trials. As well as increasing our 
understanding of the clinical effects and limitations of radia-
tion therapy in the management of patients with GBM, our 
data support the concept that new potential treatments for 
GBM should be evaluated in clinically meaningful 3D models 
before proceeding to in vivo and clinical testing. Our findings 
support the 3D-Alvetex model as a platform for modeling drug 
and radiation responses in this cancer of unmet need.
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